Skip to Main Content

Paper Details

Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
Adv Ther
3
2022
Author NameAffiliation
Bijal ShahMoffitt Cancer Center
  • 1 - 1

Datasets

Release 1.2